Literature DB >> 28291481

Self-Reported Visual Quality of Life After Combat Ocular Trauma.

Andrew McLaughlin1, Marcus H Colyer1, Denise S Ryan2, Rose K Sia2, Eric D Weichel3, Andrew Spiegelman4, S G Eaddy5, Robert A Mazzoli4, Kraig S Bower6.   

Abstract

OBJECTIVES: To describe the visual outlook and quality of life of service members after combat ocular trauma.
METHODS: In a single-center, prospective observational study of service members sustaining ocular trauma, participants underwent a series of ocular examinations and noninvasive tests, including the National Eye Institute Visual Functioning Questionnaire (VFQ-25).
RESULTS: Of the 165 enrolled participants, 137 completed the VFQ-25. The mean VFQ-25 composite score was 74.4 ± 20.7 (range: 1.4-100). Among 118 participants with visual acuity assessment, 92% had best corrected visual acuity (BCVA) of 20/20 or better in at least one eye. Among participants with severe vision loss (BCVA ≤20/200), there was no statistically significant difference in self-reported general health compared to those without severe vision loss (p = 0.17). However, there was a significantly lower visual quality of life reported in the composite score and all of the 11 subscales of the VFQ-25.
CONCLUSIONS: While this study provides evidence that combat ocular trauma is associated with a lower visual quality of life, limitations include the relatively small sample size and the limited documentation of the use of eye protection at time of injury among participants. Reprint &
Copyright © 2017 Association of Military Surgeons of the U.S.

Entities:  

Mesh:

Year:  2017        PMID: 28291481     DOI: 10.7205/MILMED-D-16-00139

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  1 in total

1.  Visual Rehabilitation With Contact Lenses Following Open Globe Trauma.

Authors:  Angelica C Scanzera; Grace Dunbar; Vidhi Shah; Maria Soledad Cortina; Yannek I Leiderman; Ellen Shorter
Journal:  Eye Contact Lens       Date:  2021-05-01       Impact factor: 3.152

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.